These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33610258)

  • 1. Investigation of isepamicin in vitro efficiency in Gram negative bacteria efficacy of isepamicin.
    Yeliz TC; Ali HB; Sarah AF; Sreylis N; Kubra HU; Asuman B
    Indian J Med Microbiol; 2021 Jan; 39(1):59-62. PubMed ID: 33610258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
    Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT
    J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of aminoglycoside resistance. European data.
    Van Landuyt HW; Boelaert J; Glibert B; Gordts B; Verbruggen AM
    Am J Med; 1986 Jun; 80(6B):76-81. PubMed ID: 3089007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of aminoglycosides against clinical isolates of Acinetobacter baumannii complex and other nonfermentative Gram-negative bacilli causing healthcare-associated bloodstream infections in Taiwan.
    Liu JY; Wang FD; Ho MW; Lee CH; Liu JW; Wang JT; Sheng WH; Hseuh PR; Chang SC
    J Microbiol Immunol Infect; 2016 Dec; 49(6):918-923. PubMed ID: 26364729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antimicrobial susceptibility to isepamicin of 6,296 Enterobacteriaceae clinical isolates collected at a tertiary care university hospital in Greece.
    Maraki S; Samonis G; Karageorgopoulos DE; Mavros MN; Kofteridis D; Falagas ME
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3067-73. PubMed ID: 22391548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibility of non-fermenting Gram-negative isolates to isepamicin in a region with high antibiotic resistance.
    Samonis G; Maraki S; Vouloumanou EK; Georgantzi GG; Kofteridis DP; Falagas ME
    Eur J Clin Microbiol Infect Dis; 2012 Nov; 31(11):3191-8. PubMed ID: 22752194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility of gentamicin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to netilmicin and selected aminoglycoside antibiotics.
    Meyer RD; Draus LL; Pasieczinik KA
    Antimicrob Agents Chemother; 1976 Oct; 10(4):677-81. PubMed ID: 825036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of isepamicin and other antibiotics against gram-negative bacilli from intensive care units (ICU) in Belgium.
    Belgian Isepamicin Multicenter Study Group
    Acta Clin Belg; 2001; 56(5):307-15. PubMed ID: 11774843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of gentamicin and/or tobramycin resistant gram-negative bacilli to seven aminoglycosides.
    Watanakunakorn C; Kauffman CA
    Infection; 1978; 6(3):111-5. PubMed ID: 98451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invitro comparative evaluation of aminoglycosides at a cancer centre.
    Biswas SK; Kelkar RS
    Indian J Cancer; 2002; 39(4):135-8. PubMed ID: 12928571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The major aminoglycoside-modifying enzyme AAC(3)-II found in Escherichia coli determines a significant disparity in its resistance to gentamicin and amikacin in China.
    Xiao Y; Hu Y
    Microb Drug Resist; 2012 Feb; 18(1):42-6. PubMed ID: 22066787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro comparison of netilmicin, a semisynthetic derivative of sisomicin, and four other aminoglycoside antibiotics.
    Kabins SA; Nathan C; Cohen S
    Antimicrob Agents Chemother; 1976 Jul; 10(1):139-45. PubMed ID: 825021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Aminoglycoside-Modifying Enzymes (AMEs) in Resistance to Aminoglycosides among Clinical Isolates of
    Ahmadian L; Norouzi Bazgir Z; Ahanjan M; Valadan R; Goli HR
    Biomed Res Int; 2021; 2021():7077344. PubMed ID: 34471641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of nosocomial isolates against a new aminoglycoside isepamicin.
    Kapil A; Bali R; Das BK
    Indian J Med Res; 2001 Feb; 113():60-2. PubMed ID: 21910285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin--a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups.
    Miller GH; Sabatelli FJ; Naples L; Hare RS; Shaw KJ
    J Chemother; 1995 Jun; 7 Suppl 2():31-44. PubMed ID: 8622109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminoglycoside-modifying enzyme and 16S ribosomal RNA methyltransferase genes among a global collection of Gram-negative isolates.
    Costello SE; Deshpande LM; Davis AP; Mendes RE; Castanheira M
    J Glob Antimicrob Resist; 2019 Mar; 16():278-285. PubMed ID: 30389638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A laboratory assessment of the activities of four aminoglycosides.
    Schrire L; Robinson RG; Koornhof HJ
    S Afr Med J; 1984 Jun; 65(23):922-4. PubMed ID: 6427946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sensitivity of Pseudomonas aeruginosa to amikacin and to isepamicin in surgery and in intensive care].
    Vincent P; Vachée A; Izard D
    Pathol Biol (Paris); 1997 Nov; 45(9):771-5. PubMed ID: 9538477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminoglycoside resistance patterns in Turkey.
    Akalin HE; Torun M; Alacam R
    Scand J Infect Dis; 1988; 20(2):199-203. PubMed ID: 2840733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of aminoglycoside--modifying enzymes in resistance of Gram-negative rods].
    Jakoniuk P; Wieczorek P; Sacha PT; Zalewska M; Leszczyńska K
    Med Dosw Mikrobiol; 2006; 58(4):363-70. PubMed ID: 17642314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.